<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03163862</url>
  </required_header>
  <id_info>
    <org_study_id>0001</org_study_id>
    <nct_id>NCT03163862</nct_id>
  </id_info>
  <brief_title>G-CSF Administration in IVF in a Preferable Preceptive Endometrium Score</brief_title>
  <official_title>Granulocyte Stimulating Factor (G-CSF) to Increase the Rate of Implantation Success in IVF Patients in Preferable Preceptive Endometrium Scroe</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istishari Arab Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Salem Abu Khyzaran</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nizam Najeeb</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Istishari Arab Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a controlled preminary trial intended to increase the implantation rate of IVF
      cycles, by using more than one known procedure, endometrial scratching, evaluating the status
      of the adhesive factors as αVβ3 integrin, L-selectin ligand MECA-79, E-cadherin and ICAM-1,
      as a determinant for intervention by G-CSF, according to a score that can be done on a small
      sample obtained during scratching, then give G-CSF for the scores less than 4 intrauterine
      and subcutaneously.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Placebo: CONTROL patients treated with PLACEBO (saline solution) from the day of embryo
      transfer through the day of beta hCG test Drug&amp; scratching CONTROL saline infusion every day
      from the day of embryo transfer through the day of beta HCG test Other Name: SALINE INFUSION
      Experimental: G-CSF group patients treated with G-CSF if the biopsy adhesive score 1-3 only

        1. Endometrial scratching and adhesive factor score, day 21-24 cycle prior to IVF//0rv day
           3 of IVF cycle not planned before.

        2. Drug &amp;scratching : G-CSF group

      1- 300 µg trans cervical intrauterine of G-CSF was administered at the oocyte retrieval day,
      2- subcutaneous 300 micrograms G-CSF on the day of embryo transfer Comparative group patients
      not treated with G-CSF after scratching if the biopsy adhesive score 4 only

      Scratching only :

      Patients undergoing scratching on day 21-24 of prior IVF cycle/ and on day 5 of IVF cycle
      with biopsy score of 4.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2017</start_date>
  <completion_date type="Anticipated">January 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>clinical pregnancy per women randomized</measure>
    <time_frame>4 weeks</time_frame>
    <description>pregnancy diagnosed by ultrasonographic visualisation of one or more gestational sacs, including ectopic pregnancy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>setting a score of precepative endometrium</measure>
    <time_frame>12 months</time_frame>
    <description>Evaluation of the endometrial biopsy and setting a receptive score/ adhesive factors of the endometrium</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Women Infertility</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients treated with infusion of PLACEBO (saline solution) from the day of embryo transfer through the day of beta hCG test</description>
  </arm_group>
  <arm_group>
    <arm_group_label>G-CSF group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients treated with G-CSF if the biopsy adhesive score 1-3 only, by Endometrial scratching and adhesive factor scoring on day 21-24 cycle prior to IVF//or day 3 of IVF cycle not planned before.
The dose of G-CSF is 300 µg by trans cervical intrauterine route administered at the oocyte retrieval day, Ans subcutaneous 300µg G-CSF on the day of embryo transfer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparative group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>patients not treated with G-CSF after scratching if the biopsy adhesive score 4 only</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Endometrial scratch</intervention_name>
    <description>the intervention group, endometrial biopsy will be performed with a pipelle de Cornier® (Laboratoires Prodimed, Neully-En-Thelle, France). The pipelle was introduced gently through the cervix up to the uterine fundus. the examiner applied regular back-and-forth movements (2-4 cm) during a period of 30 s. The obtained specimens will be sent for histology evaluation.</description>
    <arm_group_label>G-CSF group</arm_group_label>
    <arm_group_label>Comparative group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>G-CSF administration</intervention_name>
    <description>1- 300 µg trans cervical intrauterine of G-CSF was administered at the oocyte retrieval day, subcutaneous 300 micrograms G-CSF on the day of embryo transfer</description>
    <arm_group_label>G-CSF group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline Solution</intervention_name>
    <description>saline infusion every day from the day of embryo transfer through the day of beta HCG test</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ALL Women aged &lt; 40 years who would be submitted to oocyte retrieval and embryo
             transfer IN IVF cycle.

        Exclusion Criteria:

          -  • contraindications for G-CSF treatment (sickle cell disease, chronic neutropenia,
             known past or present malignancy, renal insufficiency, upper respiratory infection,
             pneumonia, and congenital fructose intolerance)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Women aged &lt; 40 years who would be submitted to oocyte retrieval and embryo transfer</gender_description>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 21, 2017</study_first_submitted>
  <study_first_submitted_qc>May 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 23, 2017</study_first_posted>
  <last_update_submitted>June 16, 2017</last_update_submitted>
  <last_update_submitted_qc>June 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Istishari Arab Hospital</investigator_affiliation>
    <investigator_full_name>Areej Khatib</investigator_full_name>
    <investigator_title>Pathology &amp; clinical labs head department</investigator_title>
  </responsible_party>
  <keyword>IVF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

